Capecitabine
- PDF / 151,672 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 43 Downloads / 144 Views
1 S
Loss of fingerprints, and hand and foot syndrome: case report A 73-year-old woman developed hand and foot syndrome and had loss of fingerprints during treatment with capecitabine for breast cancer. The woman presented in November 1990 with a mass in her left breast. She underwent left mastectomy in another hospital and her postoperative pathology revealed stage IIA breast cancer (pT2N0M0). Subsequently, she received several therapies including CMF chemotherapy (cyclophosphamide, methotrexate and fluorouracil), tamoxifen, TP chemotherapy (docetaxel and cisplatin), letrozole and exemestane. However, she had disease progression with metastases. Therefore, in April 2017, she was started on 21 days cycles of combination chemotherapy with IV infusion of docetaxel and oral capecitabine [Xeloda] 1500mg two times daily on days 1–14. After 10 days of combination chemotherapy, her skin on feet and hands was noted as thinner. After cycle 2, she developed pain in feet and hands with thin texture of the fingerprints. She had difficulty in opening fingerprint lock of her home. Her skin at interphalangeal joints became swollen and red. After third cycle, the hand and foot syndrome deteriorated with peeling and thinning of the skin of toes, fingers and interphalangeal joints. Additionally, she had loss of fingerprints and gradual loss of texture of the palm, which resulted in inability to open the fingerprint lock. During the fourth cycle, the peeling of skin of hands and feet slowly aggravated resulting in bleeding and chapping. She was diagnosed with grade IV hand and foot syndrome. The woman was treated with petrolatum [Vaseline]. Her fifth cycle was postponed for 2 weeks. Eventually, the hand and foot syndrome slightly improved. During the firth and sixth cycles, the dose of capecitabine was reduced to 1000mg daily. She received last dose of chemotherapy on 10 August 2017. Due to severe hand and foot syndrome, she discontinued the chemotherapy and remained on observation. After 17 months, she had no disease progression. Zhao J, et al. Loss of fingerprints as a side effect of capecitabine therapy: case report and literature review. Oncology Research 28: 103-106, No. 1, 7 Feb 2020. Available 803502613 from: URL: http://doi.org/10.3727/096504019X15605078731913
0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 26 Sep 2020 No. 1823
Data Loading...
